Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis
Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the e...
Saved in:
| Published in | PloS one Vol. 19; no. 12; p. e0310900 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
12.12.2024
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait.
A comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges'g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls.
A total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: -1.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was -0.366 (95% CI: -0.650 to -0.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group.
Rivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option. |
|---|---|
| AbstractList | Background & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait.MethodsA comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges’g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls.ResultsA total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: −1.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was −0.366 (95% CI: −0.650 to −0.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group.ConclusionRivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option. Background & aims Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait. Methods A comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges’g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls. Results A total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: −1.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was −0.366 (95% CI: −0.650 to −0.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group. Conclusion Rivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option. Background & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait.MethodsA comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges'g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls.ResultsA total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: -1.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was -0.366 (95% CI: -0.650 to -0.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group.ConclusionRivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option. Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait. A comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges'g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls. A total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: -1.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was -0.366 (95% CI: -0.650 to -0.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group. Rivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option. Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait.BACKGROUND & AIMSGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait disorders, which are associated with cholinergic deficits. We conducted a systematic review and meta-analysis to investigate the effects of rivastigmine on improvement in gait.A comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges'g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls.METHODSA comprehensive literature search was conducted using Medical Subject Heading (MeSH) terms and text keywords related to gait and falls after rivastigmine treatment for neurodegenerative disorders. The intervention (rivastigmine), comparison (control or no treatment), and outcomes of improvement in gait speed and fall were assessed from database inception to April 2024. References and collected data were meticulously reviewed to ensure the integrity of the included studies. Standardized mean differences (SMDs) and Hedges'g, along with their 95% confidence intervals (Cls), were calculated for gait speed and number of falls.A total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: -1.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was -0.366 (95% CI: -0.650 to -0.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group.RESULTSA total of 222 articles were identified during the initial search across different electronic databases, 50 including PubMed (n = 23), Cochrane (n = 19), Embase (n = 139), Scopus (n = 38), and a manual search (n = 3). Finally, we conducted a systematic review and meta-analysis focusing on the final four studies, encompassing 286 participants. The pooled SMD for the overall gait speed without a comparison group was 0.761 (95% CI: -1.165 to 2.688), indicating no significant improvement in gait speed. For the overall number of falls between the rivastigmine treatment and control groups, the pooled SMD was -0.366 (95% CI: -0.650 to -0.083). A statistically significant reduction in the number of falls was observed in the rivastigmine group than in the control group.Rivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option.CONCLUSIONRivastigmine treatment in patients with neurodegenerative disorders tend to improve gait speed and significantly reduces fall incidence. Given the limited efficacy of current treatments for gait disturbances and falls, dual cholinesterase inhibitors like rivastigmine could be a promising therapeutic option. |
| Author | Lee, Yungjin Shin, Jieun Shim, Sung Ryul Kim, Jong-Yeup Kwon, Kyum-Yil Lee, Seon-Min |
| AuthorAffiliation | 2 Department of Otorhinolaryngology-Head and Neck Surgery, Konyang University College of Medicine, Daejeon, Republic of Korea 4 Department of Rehabilitation Medicine, Konyang University College of Medicine, Daejeon, Republic of Korea King Abdulaziz University, SAUDI ARABIA 1 Department of Biomedical Informatics, Konyang University College of Medicine, Daejeon, Republic of Korea 5 Department of Neurology, Konyang University College of Medicine, Daejeon, Republic of Korea 3 Department of Neurology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea 6 Myunggok Medical Research Institute, Konyang University College of Medicine, Daejeon, Republic of Korea |
| AuthorAffiliation_xml | – name: 2 Department of Otorhinolaryngology-Head and Neck Surgery, Konyang University College of Medicine, Daejeon, Republic of Korea – name: 1 Department of Biomedical Informatics, Konyang University College of Medicine, Daejeon, Republic of Korea – name: 5 Department of Neurology, Konyang University College of Medicine, Daejeon, Republic of Korea – name: King Abdulaziz University, SAUDI ARABIA – name: 4 Department of Rehabilitation Medicine, Konyang University College of Medicine, Daejeon, Republic of Korea – name: 6 Myunggok Medical Research Institute, Konyang University College of Medicine, Daejeon, Republic of Korea – name: 3 Department of Neurology, Soonchunhyang University College of Medicine, Seoul, Republic of Korea |
| Author_xml | – sequence: 1 givenname: Sung Ryul surname: Shim fullname: Shim, Sung Ryul – sequence: 2 givenname: Jong-Yeup orcidid: 0000-0003-1230-9307 surname: Kim fullname: Kim, Jong-Yeup – sequence: 3 givenname: Kyum-Yil surname: Kwon fullname: Kwon, Kyum-Yil – sequence: 4 givenname: Jieun surname: Shin fullname: Shin, Jieun – sequence: 5 givenname: Yungjin surname: Lee fullname: Lee, Yungjin – sequence: 6 givenname: Seon-Min orcidid: 0000-0003-0554-0906 surname: Lee fullname: Lee, Seon-Min |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39666629$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1vGyEQhlGVqknc_oOqReqlF6ewsLD0EkVR2kaK1EvuaAyzDtYuuLB25H9fEjtRUpULaObRyzsfp-QopoiEfOTsjAvNv63SJkcYztY1fMYEZ4axN-SEG9HMVcPE0Yv3MTktZcVYKzql3pFjYVQ9jTkh5arv0U2Fpp7msIUyheUYItIU6RLCREOka5gCxsrch-mORtzk5HGJEXNNbJH6UFL2mMt3ekHLrkw41oSjGbcB7ylET0ecYA7V7q6E8p687WEo-OFwz8jtj6vby1_zm98_ry8vbuZOajXNAZw3su28Z13vVC-UEAoa2S0kaI6ecYEACnhnmOFtpXTbKNdBwzQ3vZiRz3vZ9ZCKPbSrWMGl0F1raltm5HpP-AQru85hhLyzCYJ9DKS8tJBrJQNa3WrJndam106CZ6bnjQTHF9K1CykWVev88NtmMaJ3tWEZhleirzMx3Nll2lrOldDCiKrw9aCQ058NlsmOoTgcBoiYNo_G69BEnWFFv_yD_r-8Ty8tPXt5mn4F5B5wOZWSsX9GOLMPS_Ykax-WzB6WTPwFtoXIfg |
| Cites_doi | 10.1212/WNL.0b013e3181c1ded6 10.1002/jrsm.1164 10.1016/S0306-4522(01)00613-3 10.1016/S1474-4422(15)00389-0 10.3390/diseases11030089 10.1185/03007990152673800 10.1080/09638288.2017.1329357 10.1002/mds.21720 10.4178/epih.e2019008 10.1371/journal.pmed.1000097 10.1007/s40268-014-0038-8 10.1016/0301-0082(95)00013-L 10.2174/1389201015666140827104918 10.1016/j.neubiorev.2018.12.017 10.1016/0306-4522(83)90108-2 10.1136/jnnp-2014-308764 10.18433/J3MK59 10.1016/j.jchemneu.2020.101752 10.1017/S1461145705005833 10.3389/fnhum.2017.00353 10.1111/jnc.13899 10.2307/2533446 10.1002/syn.10165 10.1093/brain/aws373 10.1016/j.jchemneu.2016.11.009 10.1016/j.neubiorev.2016.02.012 10.1159/000438824 10.1186/s12883-021-02098-8 10.1007/s00415-017-8620-y 10.1038/s41531-021-00251-1 10.1111/j.1532-5415.2008.01657.x 10.1016/j.jphys.2022.11.005 10.1016/j.parkreldis.2019.02.017 10.1016/S0966-6362(01)00156-4 10.1212/WNL.0b013e3181f6128c 10.1136/bmj.l4898 10.21032/jhis.2016.41.1.123 10.1136/bmj.316.7124.61 10.2147/CIA.S129145 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2024 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. 2024 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 Shim et al 2024 Shim et al 2024 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: Copyright: © 2024 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. – notice: 2024 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 Shim et al 2024 Shim et al – notice: 2024 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0310900 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central ProQuest Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection Biological Sciences Agricultural Science Database ProQuest Health & Medical Collection Medical Database ProQuest Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Agricultural Science Database MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| DocumentTitleAlternate | Rivastigmine and gait |
| EISSN | 1932-6203 |
| ExternalDocumentID | 3143785920 oai_doaj_org_article_75741c779f7c4ad09f124ac1b4c5b43b PMC11637393 39666629 10_1371_journal_pone_0310900 |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. ADRAZ BBORY CGR CUY CVF ECM EIF IPNFZ NPM RIG 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c476t-aacd9458dd08fc6f36336a248b4a71ed013eaa6a1890915d087526c8a20719f3 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Wed Aug 13 01:18:51 EDT 2025 Wed Aug 27 01:26:13 EDT 2025 Thu Aug 21 18:29:29 EDT 2025 Fri Jul 11 12:40:40 EDT 2025 Fri Jul 25 11:16:20 EDT 2025 Wed Feb 19 02:03:54 EST 2025 Tue Jul 01 02:40:40 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | Copyright: © 2024 Shim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c476t-aacd9458dd08fc6f36336a248b4a71ed013eaa6a1890915d087526c8a20719f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Competing Interests: The authors have declared that no competing interests exist. |
| ORCID | 0000-0003-1230-9307 0000-0003-0554-0906 |
| OpenAccessLink | https://doaj.org/article/75741c779f7c4ad09f124ac1b4c5b43b |
| PMID | 39666629 |
| PQID | 3143785920 |
| PQPubID | 1436336 |
| ParticipantIDs | plos_journals_3143785920 doaj_primary_oai_doaj_org_article_75741c779f7c4ad09f124ac1b4c5b43b pubmedcentral_primary_oai_pubmedcentral_nih_gov_11637393 proquest_miscellaneous_3146663538 proquest_journals_3143785920 pubmed_primary_39666629 crossref_primary_10_1371_journal_pone_0310900 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-12 |
| PublicationDateYYYYMMDD | 2024-12-12 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2024 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | WL Inglis (pone.0310900.ref026) 1995; 47 G Yogev-Seligmann (pone.0310900.ref002) 2008; 23 KA Chung (pone.0310900.ref007) 2010; 75 JAC Sterne (pone.0310900.ref016) 2019; 366 K Ramakrishna (pone.0310900.ref031) 2023; 11 AA Veroniki (pone.0310900.ref013) 2016; 7 O Beauchet (pone.0310900.ref038) 2017; 11 S Lord (pone.0310900.ref040) 2017; 264 M Egger (pone.0310900.ref015) 1998; 316 EJ Henderson (pone.0310900.ref005) 2016; 15 D Moher (pone.0310900.ref010) 2009; 6 Z Li (pone.0310900.ref019) 2015; 74 SN Rai (pone.0310900.ref030) 2020; 104 C Annweiler (pone.0310900.ref004) 2013; 136 G Pagano (pone.0310900.ref008) 2015; 86 SR Shim (pone.0310900.ref012) 2019; 41 H Hunter (pone.0310900.ref039) 2018; 40 F Assal (pone.0310900.ref006) 2008; 56 T Gurevich (pone.0310900.ref018) 2014; 14 B. Falkenburger (pone.0310900.ref029) 2017; 140 AW Andrews (pone.0310900.ref037) 2023; 69 MA Babizhayev (pone.0310900.ref001) 2014; 15 TA Podruchny (pone.0310900.ref027) 2003; 48 PN Tripathi (pone.0310900.ref041) 2024; 14 CB Begg (pone.0310900.ref014) 1994; 50 N Kandiah (pone.0310900.ref028) 2017; 12 NH Greig (pone.0310900.ref034) 2001; 17 R Morris (pone.0310900.ref022) 2016; 64 RM Lane (pone.0310900.ref033) 2006; 9 J Wilson (pone.0310900.ref021) 2019; 100 S-R Shim (pone.0310900.ref011) 2016; 41 M Woollacott (pone.0310900.ref025) 2002; 16 SK Yadav (pone.0310900.ref042) 2017; 80 pone.0310900.ref017 H Shimura (pone.0310900.ref020) 2021; 21 R Morris (pone.0310900.ref023) 2019; 63 M Singh (pone.0310900.ref032) 2024; 14 RS Naik (pone.0310900.ref036) 2009; 12 MM Mesulam (pone.0310900.ref024) 1983; 10 NI Bohnen (pone.0310900.ref003) 2009; 73 JH Chen (pone.0310900.ref009) 2021; 7 MM Mesulam (pone.0310900.ref035) 2002; 110 |
| References_xml | – volume: 73 start-page: 1670 issue: 20 year: 2009 ident: pone.0310900.ref003 article-title: History of falls in Parkinson disease is associated with reduced cholinergic activity publication-title: Neurology doi: 10.1212/WNL.0b013e3181c1ded6 – volume: 7 start-page: 55 issue: 1 year: 2016 ident: pone.0310900.ref013 article-title: Methods to estimate the between-study variance and its uncertainty in meta-analysis publication-title: Res Synth Methods doi: 10.1002/jrsm.1164 – volume: 110 start-page: 627 issue: 4 year: 2002 ident: pone.0310900.ref035 article-title: Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine publication-title: Neuroscience doi: 10.1016/S0306-4522(01)00613-3 – volume: 15 start-page: 249 issue: 3 year: 2016 ident: pone.0310900.ref005 article-title: Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(15)00389-0 – volume: 11 issue: 3 year: 2023 ident: pone.0310900.ref031 article-title: WNT-beta Catenin Signaling as a Potential Therapeutic Target for Neurodegenerative Diseases: Current Status and Future Perspective publication-title: Diseases doi: 10.3390/diseases11030089 – volume: 17 start-page: 159 issue: 3 year: 2001 ident: pone.0310900.ref034 article-title: A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase publication-title: Curr Med Res Opin doi: 10.1185/03007990152673800 – ident: pone.0310900.ref017 – volume: 40 start-page: 2236 issue: 19 year: 2018 ident: pone.0310900.ref039 article-title: Longitudinal falls data in Parkinson’s disease: feasibility of fall diaries and effect of attrition publication-title: Disabil Rehabil doi: 10.1080/09638288.2017.1329357 – volume: 23 start-page: 329 issue: 3 year: 2008 ident: pone.0310900.ref002 article-title: The role of executive function and attention in gait publication-title: Mov Disord doi: 10.1002/mds.21720 – volume: 41 start-page: e2019008 year: 2019 ident: pone.0310900.ref012 article-title: Intervention meta-analysis: application and practice using R software publication-title: Epidemiol Health doi: 10.4178/epih.e2019008 – volume: 14 start-page: 33 year: 2024 ident: pone.0310900.ref032 article-title: A Comprehensive Review and Androgen Deprivation Therapy and Its Impact on Alzheimer’s Disease Risk in Older Men with Prostate Cancer publication-title: Degener Neurol Neuromuscul Dis – volume: 6 start-page: e1000097 issue: 7 year: 2009 ident: pone.0310900.ref010 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 14 start-page: 57 issue: 2 year: 2014 ident: pone.0310900.ref018 article-title: Effect of rivastigmine on mobility of patients with higher-level gait disorder: a pilot exploratory study publication-title: Drugs R D doi: 10.1007/s40268-014-0038-8 – volume: 47 start-page: 1 issue: 1 year: 1995 ident: pone.0310900.ref026 article-title: The pedunculopontine tegmental nucleus: where the striatum meets the reticular formation publication-title: Prog Neurobiol doi: 10.1016/0301-0082(95)00013-L – volume: 15 start-page: 738 issue: 8 year: 2014 ident: pone.0310900.ref001 article-title: Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities publication-title: Curr Pharm Biotechnol doi: 10.2174/1389201015666140827104918 – volume: 100 start-page: 344 year: 2019 ident: pone.0310900.ref021 article-title: The neural correlates of discrete gait characteristics in ageing: A structured review publication-title: Neurosci Biobehav Rev doi: 10.1016/j.neubiorev.2018.12.017 – volume: 10 start-page: 1185 issue: 4 year: 1983 ident: pone.0310900.ref024 article-title: Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6) publication-title: Neuroscience doi: 10.1016/0306-4522(83)90108-2 – volume: 86 start-page: 767 issue: 7 year: 2015 ident: pone.0310900.ref008 article-title: Cholinesterase inhibitors for Parkinson’s disease: a systematic review and meta-analysis publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2014-308764 – volume: 12 start-page: 79 issue: 1 year: 2009 ident: pone.0310900.ref036 article-title: Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice publication-title: J Pharm Pharm Sci doi: 10.18433/J3MK59 – volume: 104 start-page: 101752 year: 2020 ident: pone.0310900.ref030 article-title: Advancement in the modelling and therapeutics of Parkinson’s disease publication-title: J Chem Neuroanat doi: 10.1016/j.jchemneu.2020.101752 – volume: 9 start-page: 101 issue: 1 year: 2006 ident: pone.0310900.ref033 article-title: Targeting acetylcholinesterase and butyrylcholinesterase in dementia publication-title: Int J Neuropsychopharmacol doi: 10.1017/S1461145705005833 – volume: 11 start-page: 353 year: 2017 ident: pone.0310900.ref038 article-title: Guidelines for Assessment of Gait and Reference Values for Spatiotemporal Gait Parameters in Older Adults: The Biomathics and Canadian Gait Consortiums Initiative publication-title: Front Hum Neurosci doi: 10.3389/fnhum.2017.00353 – volume: 140 start-page: 688 issue: 5 year: 2017 ident: pone.0310900.ref029 article-title: ExPPNing how acetylcholine improves gait in Parkinson’s disease: An Editorial Highlight for ’Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait’ publication-title: J Neurochem doi: 10.1111/jnc.13899 – volume: 50 start-page: 1088 issue: 4 year: 1994 ident: pone.0310900.ref014 article-title: Operating characteristics of a rank correlation test for publication bias publication-title: Biometrics doi: 10.2307/2533446 – volume: 48 start-page: 39 issue: 1 year: 2003 ident: pone.0310900.ref027 article-title: In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers publication-title: Synapse doi: 10.1002/syn.10165 – volume: 136 start-page: 859 issue: Pt 3 year: 2013 ident: pone.0310900.ref004 article-title: Motor cortex and gait in mild cognitive impairment: a magnetic resonance spectroscopy and volumetric imaging study publication-title: Brain doi: 10.1093/brain/aws373 – volume: 14 start-page: 47 year: 2024 ident: pone.0310900.ref041 article-title: Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants publication-title: Degener Neurol Neuromuscul Dis – volume: 80 start-page: 1 year: 2017 ident: pone.0310900.ref042 article-title: Mucuna pruriens reduces inducible nitric oxide synthase expression in Parkinsonian mice model publication-title: J Chem Neuroanat doi: 10.1016/j.jchemneu.2016.11.009 – volume: 64 start-page: 326 year: 2016 ident: pone.0310900.ref022 article-title: Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease publication-title: Neurosci Biobehav Rev doi: 10.1016/j.neubiorev.2016.02.012 – volume: 74 start-page: 86 issue: 1–2 year: 2015 ident: pone.0310900.ref019 article-title: Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson’s Disease Patients publication-title: Eur Neurol doi: 10.1159/000438824 – volume: 21 start-page: 61 issue: 1 year: 2021 ident: pone.0310900.ref020 article-title: Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease publication-title: BMC Neurol doi: 10.1186/s12883-021-02098-8 – volume: 264 start-page: 2268 issue: 11 year: 2017 ident: pone.0310900.ref040 article-title: Natural history of falls in an incident cohort of Parkinson’s disease: early evolution, risk and protective features publication-title: J Neurol doi: 10.1007/s00415-017-8620-y – volume: 7 start-page: 103 issue: 1 year: 2021 ident: pone.0310900.ref009 article-title: Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis publication-title: NPJ Parkinsons Dis doi: 10.1038/s41531-021-00251-1 – volume: 56 start-page: 946 issue: 5 year: 2008 ident: pone.0310900.ref006 article-title: Galantamine improves gait performance in patients with Alzheimer’s disease publication-title: J Am Geriatr Soc doi: 10.1111/j.1532-5415.2008.01657.x – volume: 69 start-page: 47 issue: 1 year: 2023 ident: pone.0310900.ref037 article-title: Normal gait speed varies by age and sex but not by geographical region: a systematic review publication-title: J Physiother doi: 10.1016/j.jphys.2022.11.005 – volume: 63 start-page: 20 year: 2019 ident: pone.0310900.ref023 article-title: Overview of the cholinergic contribution to gait, balance and falls in Parkinson’s disease publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2019.02.017 – volume: 16 start-page: 1 issue: 1 year: 2002 ident: pone.0310900.ref025 article-title: Attention and the control of posture and gait: a review of an emerging area of research publication-title: Gait Posture doi: 10.1016/S0966-6362(01)00156-4 – volume: 75 start-page: 1263 issue: 14 year: 2010 ident: pone.0310900.ref007 article-title: Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease publication-title: Neurology doi: 10.1212/WNL.0b013e3181f6128c – volume: 366 start-page: l4898 year: 2019 ident: pone.0310900.ref016 article-title: RoB 2: a revised tool for assessing risk of bias in randomised trials publication-title: Bmj doi: 10.1136/bmj.l4898 – volume: 41 start-page: 123 issue: 1 year: 2016 ident: pone.0310900.ref011 article-title: Intervention Meta-Analysis Using STATA Software publication-title: J Health Info Stat doi: 10.21032/jhis.2016.41.1.123 – volume: 316 start-page: 61 issue: 7124 year: 1998 ident: pone.0310900.ref015 article-title: Bias in location and selection of studies publication-title: BMJ doi: 10.1136/bmj.316.7124.61 – volume: 12 start-page: 697 year: 2017 ident: pone.0310900.ref028 article-title: Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia publication-title: Clin Interv Aging doi: 10.2147/CIA.S129145 |
| SSID | ssj0053866 |
| Score | 2.4641635 |
| SecondaryResourceType | review_article |
| Snippet | Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and higher-level gait... Background & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and... Background & aimsGait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and... Background & aims Gait disturbances are commonly observed in patients with neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and... |
| SourceID | plos doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | e0310900 |
| SubjectTerms | Accidental Falls - prevention & control Accidental Falls - statistics & numerical data Alzheimer Disease - complications Alzheimer Disease - drug therapy Alzheimer Disease - physiopathology Alzheimer's disease Bias Biology and Life Sciences Cholinergics Cholinesterase Cholinesterase inhibitors Cholinesterase Inhibitors - pharmacology Cholinesterase Inhibitors - therapeutic use Cognitive ability Collaboration Dementia Disturbances Executive function Falls Gait Gait - drug effects Gait - physiology Health services Humans Literature reviews Medicine and Health Sciences Meta-analysis Neurodegenerative diseases Neurodegenerative Diseases - complications Neurodegenerative Diseases - drug therapy Neurodegenerative Diseases - physiopathology Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Parkinson Disease - complications Parkinson Disease - drug therapy Parkinson Disease - physiopathology Parkinson's disease Patients Physical Sciences Research and Analysis Methods Rivastigmine Rivastigmine - pharmacology Rivastigmine - therapeutic use Searching Statistical analysis Systematic review |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrZ3Lb9QwEIct1FMviLZAQx8yEgc4pG38DrcWUVVIcCpSb5HjR1mJJlWT8vczY3uXXVSJC9c4cpKZsec3if2FkHcKRDEUyqEOvWmhQFGu7oOydXSNdiyCqNC4UfjrN3X1XXy5kTdrv_rCNWEZD5wNd6ol5DyndRu1E9aftREyknVNL5zsBe9x9oWctyym8hwMo1ipslGO6-a0-OXkfhzCSYJh4o62tUSUeP3IN_05Tk9pzb-XTK7loMsX5HkRj_Q83_QOeRaGXbJThudE3xeG9Ic9MmUq8UTHSB8WvyyiNO5AUNJxoLd2MdPFQAtSdaL4LpYmsKUPt6kLnAOpL2DO6SM9p3-IzzTvdqF28PQuzLa2hWvyklxffr7-dFWX_yvUTmg119Y63wppvD8z0anIFefKMmF6YXUTPL4htVbZxrRgYekRfs-UM5aBLmkjf0W2BjDoPqEOupC9aZT0XjSMmcidF86Z6EFhOFmRemnr7j5TNLr0KU1D9ZFt16FvuuKbilygQ1bnIgM7HYDI6EpkdP-KjIrsozuXF5g6DtpQG9ky6P9w6eKnm9-ummG04ScUO4TxMZ2jUKNxU5HXOSJWN8mhclSKtRUxG7Gy8RSbLcPiRyJ6N6CKEU345n889wHZZqC8cM1Nww7J1vzwGI5AOc39cRokvwEj8RpS priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ3Lb9QwEIctKBcuqOXVQEFG4gAHtxvbsR0uqCCqCglORdpb5PixrNQmyybt38-M4912UcU1jhzH48dvxvZnQt4rEMXgKAcWWlODg6Ica4OyLLpSOx5BVGg8KPzjpzr_Jb_Pq3kOuA15W-VmTEwDte8dxshPBEzs2lQ1n31e_WF4axSuruYrNB6SR4guwy1der51uKAvK5WPywldnmTrHK_6LhwnJCaea7szHSVqP1JOL_vhPsX578bJOzPR2T55kiUkPZ1sfkAehO4pOciddKAfMkn64zMyTGzigfaRrpc3FoEaVyArad_RhV2OdNnRDFYdKEZkacJb-rBIWeBISH3Gcw6f6Cm95T7T6cwLtZ2nV2G0zGa6yXNycfbt4us5y7csMCe1Gpm1zteyMt7PTHQqCiWEslyaVlpdBo9xUmuVLU0N2qLyiMDnyhnLQZ3UUbwgex1U6CGhDrKoWlOqyntZcm6icF46Z6IHneGqgrBNXTeriaXRpAU1DT7IVHcN2qbJtinIFzTI9l0kYacH_XrR5I7V6Ao0kdO6jtpJ62d1BMViXdlKV7VStAU5RHNuPjA0tw2pIEcbE9-f_G6bDH0OF1JsF_rr9I5CpSZMQV5OLWJbSAH-o1K8LojZaSs7f7Gb0i1_J653CdoYAYWv_l-u1-QxB2WFe2pKfkT2xvV1eAPKaGzfpub_FxqdEcM priority: 102 providerName: ProQuest |
| Title | Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39666629 https://www.proquest.com/docview/3143785920 https://www.proquest.com/docview/3146663538 https://pubmed.ncbi.nlm.nih.gov/PMC11637393 https://doaj.org/article/75741c779f7c4ad09f124ac1b4c5b43b http://dx.doi.org/10.1371/journal.pone.0310900 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKe-GCKK8GyspIHOCQ1foR20FCqK26VEitEGqlvUWOH8tKbVI2KYJ_z9jxLixaJC45xI6dzHjibzz2Nwi9FgCKwVF2uatVCQ6KMHnthM69IdJQD6BChoPC5xfi7Ip_mhWzHbTK2ZoE2G117UI-qavl9fjHt58fwODfx6wNkqweGt-2jRtHqssJOPF7MDfJYKrnfB1XAOuO0cuAWnJBJywdpvtXKxuTVeT0Dxyo1223DY_-va3yj3lq-hA9SAATHw0jYh_tuOYR2k8m3OE3iWf67WPUDczFHW49Xi6-60C3cQOgE7cNnutFjxcNTrSrHQ7rtTiSX1o3j02E_yS2ibyze4eP8G9WaDyciMG6sfjG9TrXifvkCbqcnl6enOUpB0NuuBR9rrWxJS-UtRPljfBMMCY05armWhJnwyqq1kITVQLyKGwgyKfCKE0Bu5SePUW7DQj0AGEDTRS1IqKwlhNKlWfGcmOUt4BCTJGhfCXr6nZg2qhiuE2ChzLIrgq6qZJuMnQcFLKuG3iy4412Oa-S2VWyAMRkpCy9NFzbSekBz2hDam6KmrM6QwdBnasOuooBfpSqKCm0f7hS8fbiV-tisMgQZtGNa-9iHRFwHFMZejaMiPVLMvAuhaBlhtTGWNn4is2SZvE1sn4TQM6BvvD5f3T8At2nAL7CthtCD9Fuv7xzLwE89fUI3ZMzCVd1QsJ1-nGE9o5PLz5_GcXliFG0l1_FSCCU |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VcoALorwaKGAkkOCQduMktoOEUHlUW_o4LdLeIsd2lpVosmxSED-K_8hM4my7qOLWaxw5juf1je35DPBSICjGRNmFrlAZJijChIUTOixNJA0vEVRIKhQ-ORXjr8mXaTrdgD9DLQwdqxx8YueobW1ojXwvxsAuVZrx0fvFj5BujaLd1eEKjV4tjtzvX5iyNe8OP6F8X3F-8HnycRz6WwVCk0jRhlobmyWpsnakSiPKWMSx0DxRRaJl5CytC2otdKQyjKWpJcp3LozSHKNxVsbY7Q24iXF3RAYlp6v8Dl2HEL46L5bRnleG3UVdud2OgZPK6C5Fv-6SACJV_V43VwHcf89pXgp8B3fhjkesbL9XsS3YcNU92PI-oWGvPXH1m_vQ9FTIDatLtpz_1MTfcYYoltUVm-l5y-YV8zyuDaMFYNaxaVo367ogx8usZwNt3rJ9dkEzzfoSG6Yry85cq0PtyVQewOQ6pv8hbFY4odvADHaRFioSqbVJxLkqY2MTY1RpEdaYNIBwmOt80VN35N3-ncSUp5-7nGSTe9kE8IEEsnqXiLe7B_Vylns7zmWKEMxImZXSJNqOshIBkjZRkZi0SOIigG0S5_CBJr_Q2wB2BhFf3fxi1YwmTvs2unL1efeOIGAYqwAe9RqxGmSM6aoQPAtArenK2l-st1Tzbx2NeIRQnPgQH_9_XM_h1nhycpwfH54ePYHbHEEdHeeJ-A5ststz9xRBWVs860yBQX7NpvcXkctNOA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIiEuiPJqoICRQIJDuhs7sR0khApl1VKoOBRpb5Hjx7ISTZZNCuKn8e8YJ862iypuvcaR43he39iezwDPOYJiTJRtbEuZY4LCdVxarmKnE6GpQ1AhfKHw52N-8DX9OM2mG_BnqIXxxyoHn9g5alNrv0Y-YhjYhcxyOh65cCziy_7k7eJH7G-Q8jutw3UavYoc2d-_MH1r3hzuo6xfUDr5cPL-IA43DMQ6FbyNldImTzNpzFg6zR3jjHFFU1mmSiTW-DVCpbhKZI5xNTOe_p1yLRXFyJw7ht1eg-uCZYk3MTFd5XroRjgPlXpMJKOgGLuLurK7HRunL6m7EAm7CwM8wer3urkM7P57ZvNCEJzchlsBvZK9Xt22YMNWd2Ar-IeGvAwk1q_uQtPTIjekdmQ5_6k8l8cpIlpSV2Sm5i2ZVyRwujbELwaTjlnT2FnXhXfCxARm0OY12SPnlNOkL7chqjLk1LYqVoFY5R6cXMX034fNCid0G4jGLrJSJjwzJk0olY5pk2otnUGIo7MI4mGui0VP41F0e3kC059-7govmyLIJoJ3XiCrdz0Jd_egXs6KYNOFyBCOaSFyJ3SqzDh3CJaUTspUZ2XKygi2vTiHDzTFuQ5HsDOI-PLmZ6tmNHe_h6MqW59173APEpmM4EGvEatBMkxdOad5BHJNV9b-Yr2lmn_rKMUThOWeG_Hh_8f1FG6g0RWfDo-PHsFNivjOn-xJ6A5stssz-xjxWVs-6SyBQHHFlvcX14dRbg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+rivastigmine+on+gait+in+patients+with+neurodegenerative+disorders%3A+A+systematic+review+and+meta-analysis&rft.jtitle=PloS+one&rft.au=Shim%2C+Sung+Ryul&rft.au=Kim%2C+Jong-Yeup&rft.au=Kwon%2C+Kyum-Yil&rft.au=Shin%2C+Jieun&rft.date=2024-12-12&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=19&rft.issue=12&rft.spage=e0310900&rft_id=info:doi/10.1371%2Fjournal.pone.0310900&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |